| Abstract | In this review we analyse the current status of perioperative systemic chemotherapy in the treatment of transitional cell carcinoma (TCC) of the bladder; instead of summarizing each neoadjuvant or adjuvant clinical trial we focus on the advantages and disadvantages of both strategies on the basis of theoretical considerations, and outline a rationale for a better design of future studies to confirm the efficacy of perioperative chemotherapy in TCC. |
| Authors | Henrik Suttmann, Jörn Kamradt, Jan Lehmann, Michael Stöckle
(Affiliation: Department of Urology and Paediatric Urology, Saarland University Hospital, Homburg/Saar, Germany. henrik.suttmann at uniklinikum-saarland.de)
|
| Journal | BJU international
(BJU Int)
Vol. 100
Issue 6
Pg. 1225-8
(Dec 2007)
ISSN: 1464-410X England |
| PMID | 17979921
(Publication Type: Journal Article, Review)
|
| Topics |
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carcinoma, Transitional Cell
(drug therapy, therapy)
- Chemotherapy, Adjuvant
- Cystectomy
- Humans
- Perioperative Care
(methods)
- Prognosis
- Treatment Outcome
- Urinary Bladder Neoplasms
(drug therapy, therapy)
|
